Larvol Delta - ADCET02--A-clinical-stage-antibody-drug-conjugate-targeting-tissue-factor-demonstrates-strong-efficacy-in-preclinical-models-of-head-and-neck-squamous-cell-carcinoma

ADCE-T02 - Adcendo

Tivdak (tisotumab vedotin-tftv) - Genmab, Pfizer

https://www.abstractsonline.com/pp8/#!/21436/presentation/4464

Thomas Tuxen Poulsen1; Olga Ilina1; Pernille Barkholt1; Daniela Pontieri1; Jette Bomholt Lange1; Jonathan Henry Wardman1; Christophe Côme1; Christina Hjæresen1; Shu-Hui Liu2; Xun Meng3; Yue Zhang3; Dominik Mumberg1

Mar 18, 2026